AC Immune (NASDAQ:ACIU) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report published on Friday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the stock.

AC Immune Stock Down 0.4 %

Shares of ACIU opened at $2.29 on Friday. The company has a market cap of $226.57 million, a PE ratio of -4.98 and a beta of 1.23. The business has a fifty day moving average of $2.61 and a 200 day moving average of $2.98. AC Immune has a 52-week low of $2.19 and a 52-week high of $4.98.

Institutional Trading of AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in shares of AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after purchasing an additional 94,191 shares during the last quarter. Northern Trust Corp bought a new stake in shares of AC Immune during the fourth quarter worth $1,088,000. Dimensional Fund Advisors LP lifted its position in shares of AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock worth $355,000 after purchasing an additional 74,358 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of AC Immune by 9.9% during the fourth quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock worth $173,000 after purchasing an additional 5,794 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of AC Immune during the fourth quarter worth $118,000. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.